118 results
Page 2 of 6
8-K
EX-99.2
pfth53yb0myre5yprsse
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
ndp9qsmg3sd
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
wvb5a6u6xzygr78co
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
8r2kouk9v21
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
EX-99.1
bhyfkbiz1wt2fm7 nblf
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.2
l74o0idm7zx6og
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
aeu6yi uks4
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.2
j03thedy
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
g0aghi wf9j1
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.2
dh9g2j 2q
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
bjn68
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-1.1
ot4peext7d933q5qsh
14 Sep 22
Entry into a Material Definitive Agreement
9:01am
424B5
cmbdgb0z
14 Sep 22
Prospectus supplement for primary offering
7:28am
8-K
EX-99.2
i7dzn9rwns8nf
14 Sep 22
Other Events
7:05am
8-K
EX-99.1
dv3 lgdp83y
14 Sep 22
Other Events
7:05am